Lifeward Ltd. LFWD recently announced that it has received FDA 510(k) clearance for its latest innovation, the ReWalk 7 ...

Lifeward announced today that it received FDA 510(k) clearance for its latest-generation personal exoskeleton device, ReWalk ...

FDA clearance for the newest generation of its personal exoskeleton device, the ReWalk 7. The seventh generation of the ReWalk, a wearable exoskeleton that allows individuals with spinal cord injury ...

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a ...

Last week, Lifeward said full-year revenue rose to $25.7 million from $13.9 million. It said ReWalk Personal Exoskeleton sales increased by 130% in 2024, fueled by recently established Medicare ...

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical ...

Lifeward stock is trading higher on Thursday after the company announced that its ReWalk 7 received 510(k) clearance from the ...

ReWalk Robotics (NASDAQ:LFWD – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $13.00 price ...

Lifeward Ltd. announced it has received 510(k) FDA clearance for its latest personal exoskeleton device, the ReWalk 7, which enables individuals with spinal cord injuries to stand and walk.

With the ReWalk 7, we are able to deliver on that commitment, and will continue to look for opportunities to innovate and improve upon medical devices for the SCI community.” Clearance for the ...